Sunday, 20 September 2026European Markets

HOFSETH BIOCARE Stock Rises 9% So Far On Friday, Outperforms Market

Loading stream...

At 11:43 EST on Friday, shares of HOFSETH BIOCARE (HBC.OL) surged by 9.83% to close at kr3.24 at 11:43 EST - marking an upward movement from their last closing price at kr2.95. Although still 25.32% below their 52-week high of kr3.95, the increase suggests the stock is moving in an optimistic manner similar to Oslo Bors Benchmark Index_GI as a whole.

About Hofseth BioCare ASA

Hofseth BioCare ASA of Alesund, Norway serves as a provider of pet and consumer health ingredients both within Norway and internationally. Products offered include Brilliant and OmeGo salmon oils as well as ProGo Salmon Protein Powder.

Financial Health Concerns

However, despite HBC.OL's stock rally, its financial health remains cause for serious concern. Over the past year it reported negative earnings per share of kr-0.37 and its return on equity is also disconcertingly negative at 126.49% indicating significant shareholder equity losses.

Stock Stability

On a positive note, however, the value of HOFSETH BIOCARE's shares remains well above its 50-day moving average of kr2.87 and slightly above its 200-day moving average of kr2.96, suggesting relative mid- to long-term stability.

Revenue Growth and Profitability

As well, the company has witnessed impressive revenue growth; its year-on-year quarterly revenue growth increased by 45.4% year over year to reach 134.43 million during its twelve trailing months period. Unfortunately, however, EBITDA stands at a negative number at -39.65; thus raising concerns over its profitability.

Conclusion

Overall, HOFSETH BIOCARE's stock performance indicates an upward trajectory with promising revenue growth and worrying profitability metrics that call attention to the need for strategic decision-making in order to enhance shareholder returns and bolster overall financial status.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com